Efficacy and Safety of Cabozantinib for Advanced Gastrointestinal (GI) Neuroendocrine Tumors (NET) after Progression on Prior Therapy: Subgroup Analysis of the Phase 3 CABINET Trial (alliance A021602).Jonathan R. Strosberg,Tyler J. Zemla,Susan Michelle Geyer, Michael V. Knopp,Spencer Behr, Sydney Pulsipher,Jared David Acoba,Ardaman Shergill,Edward M. Wolin,Thorvardur Ragnar Halfdanarson,Bhavana Konda,Nikolaos Trikalinos,Bernard Tawfik,Nitya Prabhakar Raj,Shagufta Shaheen,Namrata Vijayvergia,Arvind Dasari,Eileen M. O'Reilly,Jeffrey A. Meyerhardt,Jennifer A. ChanJournal of Clinical Oncology（2025）引用 0|浏览6AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
